Dupixent and Narrowband UVB for Atopic Dermatitis
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Dupixent.
- Who it may be relevant to
- Registry conditions: Atopic Dermatitis. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- United States
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Single Center, Pilot Study to Evaluate the Effectiveness and Safety of Dupilumab in Combination With Narrowband UVB (nUVB) Phototherapy in the Treatment of Moderate-to-Severe Atopic Dermatitis
Overview
24 weeks open-label study with dupilumab and narrowband UVB phototherapy three times weekly for 12 weeks followed by 12 weeks of dupilumab monotherapy.
Detailed description
24 weeks open-label study with dupilumab and narrowband UVB phototherapy three times weekly for 12 weeks followed by 12 weeks of dupilumab monotherapy.
Interventions
- Drug Dupixent
dupilumab 300mg
Primary outcome measures
- Investigators Global Assessment Score of score of 0 or 1 [Time frame: 12 weeks]
Eligibility criteria
Inclusion criteria
- Male or female adult ≥ 18 years of age;
- Diagnosis of moderate to severe atopic dermatitis as defined at baseline by:
- EASI score of 16 or greater,
- IGA score of 3 or greater
- BSA of 10% or greater,
Exclusion criteria
- Subjects with previous exposure to dupilumab.
- Known or suspected hypersensitivity to dupilumab or any of its excipients.
- History of photosensitivity.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- N/A
- Model
- Single group
- Masking
- Open label
- Primary purpose
- Treatment
Study locations
United States · 1 center
- Eczema Treatment Center of New Jersey — East Windsor
Identifiers
NCT: NCT05285839 · ETC01